Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that President and CEO Jim Clemmer, along with Executive VP and CFO Stephen Trowbridge, will present at the Needham 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:00 a.m. ET. The presentation aims to showcase the company’s innovative medical technologies focused on enhancing blood flow and cancer treatment options, ultimately improving patient quality of life.
A live webcast will be available in the “Investors” section of AngioDynamics’ website, with a replay accessible post-event. The presentation highlights the company’s commitment to addressing unmet patient needs through its transformative medical solutions.